Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome

Abstract

CD10 is a cell surface neutral endopeptidase that is not consistently expressed in the stromal cells of the normal breast. Expression of CD10 is sometimes observed in the stromal cells of invasive ductal carcinoma, but its clinical significance has never been studied. Immunohistochemical examination of CD10 was performed in 123 cases of breast cancer. The median follow-up period of all patients was 8.0 years, and univariate and multivariate analyses were performed to evaluate the prognostic significance of stromal CD10 expression. There was no staining in the stromal cells of 13 non-invasive ductal carcinomas or normal breast tissue. Of 110 invasive ductal carcinomas, 20 cases (18%) in which more than 10% of the stromal cells stained positive throughout the cancer tissue were judged "positive". The frequency of positive stromal staining was significantly higher in the cases with axillary lymph-node metastasis ( P=0.038), but there were no correlations between stromal CD10 expression and age, tumor size, histologic grade, or clinical stage. The patients whose tumors contained CD10-positive stromal cells had a shorter metastasis-free interval ( P=0.0008). Univariate analysis demonstrated that patients with lymph-node metastasis also had a significantly shorter metastasis-free interval (metastasis vs no metastasis; P=0.0318). In the multivariate analysis, only CD10 remained a significant predictor for time to recurrence ( P=0.0059), and CD10 was the single significant prognostic factor for overall survival in the univariate analysis ( P=0.0021). These results suggest that stromal expression of CD10 in breast cancer is an important novel prognostic factor.

Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma

“…This dichotomy of expression was also noted, to some extent, in stromal myofibroblasts, which tended to be more commonly and extensively stained with smooth muscle actin rather than CD10, although positive staining with the latter was noted in several cases in this as well as in other studies. 8,37 In this respect, recent studies have suggested the existence of more than one type of myofibroblasts in breast lesions, which vary in their expression of smooth muscle actin and CD34. 38 It has to be added here, that it would be interesting to compare the staining results of the recently introduced nuclear myoepithelial cell marker p63 39 with the more established cytoplasmic markers for these cells in a future study.…”

Phenotypic composition of salivary gland tumors: an application of principle component analysis to tissue microarray data

“…Later studies revealed that 14-3-3s sequesters the Cdc2/cyclin B1 complex in the cytoplasm, which prevents entry into the mitotic phase, thus causing mitotic catastrophe. 18,19 CD10 is an antigen well known as common acute lymphocytic leukemia antigen (CALLA), and recently, expression of this molecule has been reported in hepatocellular carcinoma, 20 mesonephric tumors, 20 trophoblastic tumors, 20 breast cancers 21 and endometrial stromal tumors. 22 CD44 is a cellular adhesion molecule and a complex pattern of CD44 splice variants are expressed in various cancers (recently reviewed by Ponta et al).…”

Stromal Signatures of Breast Carcinogenesis in Fibroadenoma—A Pilot Study

“…The stroma of the developing breast is not positive for CD10. Stromal cells in fibroadenomas have demonstrated CD10 positivity [11], and expression has been observed in the stroma and ECM of breast cancers [10,11]. It is hypothesized CD10 may craft a specialized microenvironment to facilitate cancer cell invasion, and/ or may cross-talk with cancerous cells to speed up the cell cycle and promote cell mobility.…”

“…CD10 is believed to represent a stronger predictive factor for both tumour recurrence and death than node status, tumour size, histologic grade, or clinical size by accordance of Cox's proportional hazards regression model [11]. CD10 expression is associated with estrogen receptor-negativity, high tumour grade and decreased patient survival [10].…”